Abbott Synthroid
Executive Summary
Thyroid hormone Synthroid had 57% of the retail market on Aug. 13. FDA set a deadline of Aug. 14 for approved marketing applications for levothyroxine products; Abbott will phase-down its distribution of Synthroid to 95% of current levels by Nov. 1 while its application is pending at FDA (1"The Pink Sheet" July 16, p. 16)